WAIKOLOA, Hawaii — In this Healio Video Perspective from Retina 2026, Roger A. Goldberg, MD, MBA, discusses Encelto for the treatment of macular telangiectasia type 2.
Encelto (revakinagene taroretcel-lwey, Neurotech Pharmaceuticals) was approved for the treatment of macular telangiectasia (MacTel) type 2 in March 2025. Goldberg, of Bay Area Retina Associates, presented findings from a study that explored surgical-related adverse events associated with the implant. He and colleagues reviewed complications from six clinical trials of Encelto.
{{VIDEO}}
“We wanted to look at all of the surgical